​The Alzheimer's drug working upstream of amyloid New imaging analysis from the Phase 2a trial of a new small molecule drug shows dose-dependent preservation of whole-brain connectivity. Written byAndrea Corona

​The Alzheimer's drug working upstream of amyloid New imaging analysis from the Phase 2a trial of a new small molecule drug shows dose-dependent preservation of whole-brain connectivity. Written byAndrea Corona https://www.drugdiscoverynews.com/the-alzheimer-s-drug-working-upstream-of-amyloid-17449?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz--U0ZwnxsGXD1zAoxfxwKppQPdlU20Qgw2rMK0k5ZFS-q8JiUwJU2PjTxBfihxC7oNuX8aozXzvC5djG0YGYelklbeqhw&_hsmi=443231356&utm_content=443231356&utm_source=hs_email Most of the recent progress in Alzheimer's disease therapeutics has centered on clearing amyloid from the brain. The approval of lecanemab and donanemab has validated the amyloid hypothesis well enough to change clinical practice, but neither drug stops the disease. They slow it, modestly, in carefully selected patients. The field's attention is increasingly turning to what comes after amyloid accumulation: the cascade of synaptic damage, network disruption, and cognitive decline that amyloid pathology sets in motion but does not entirely account for.